Stories about Contraindication
- Language:
-
Media:
All
- Period:
- Period:Total
- more
Grünenthal and Averitas Pharma Announce U.S. FDA Approval of QUTENZA® for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy of the Feet
moreIDELVION® Becomes First and Only Factor IX Therapy with 21-Day Prophylactic Dosing
moreAveritas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin) 8% Patch for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
moreUCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting
moreFDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis
moreMAVENCLAD® (Cladribine Tablets) Approved As The First Short-Course Oral Treatment for Relapsing Remitting Multiple Sclerosis in Switzerland
moreOzempic® Consistently Reduced the Risk of Major Cardiovascular Events Across Type 2 Diabetes Populations at High CV Risk Regardless of Prior CV Events at Baseline
more
1